STEMCELL-TECHNOLOGIES
26.3.2024 13:01:28 CET | Business Wire | Press release
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)
The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples. Such cell-type-specific enrichment can increase the sensitivity of downstream in vitro diagnostic tests for multiple myeloma—a cancer of plasma cells—to better inform patient risk and course of treatment. Accounting for approximately 2% of all cancers in the United States1, multiple myeloma is incurable, and variable or low frequencies of CD138+ cells in bone marrow samples can impact the reliability of detecting genetic abnormalities that influence the disease’s progression. Incorporation of STEMCELL's new kit in a pre-analytical step of the diagnostic workflow can contribute to improving patient care and outcomes by enhancing the sensitivity and resolution of these downstream assays.
“STEMCELL is proud to develop the first hematopoietic cell enrichment product identified as an in vitro diagnostic device by the FDA,” said Dr. Allen Eaves, President and CEO, STEMCELL. “Creating an IVD product that improves the accuracy of information guiding the treatment of patients with multiple myeloma is a milestone achievement that reflects our commitment to make a positive impact on human health.”
The FDA identifies this new product type as a hematopoietic cell enrichment kit: a Class II IVD device for selecting specific cells from human whole blood or bone marrow, intended for use with diagnostic assays as part of the pre-analytical workflow. Agencies such as the National Comprehensive Cancer Network and the American College of Medical Genetics recommend CD138+ cell enrichment upstream of fluorescence in situ hybridization (FISH) testing for multiple myeloma; however, until now, hematopoietic cell enrichment products have not been classified as IVD devices by the FDA.
“This De Novo classification will have a permanent impact on the IVD landscape and paves the way for further innovation,” said Dr. Eaves. “STEMCELL is committed to building on this foundational work in the IVD field with novel diagnostic products and support, including supporting industry partnerships through our Diagnostics Partnerships and OEM Solutions Program.”
The EasySep™ Human Bone Marrow CD138 Positive Selection Kit is part of STEMCELL’s portfolio of EasySep™ immunomagnetic cell isolation technologies, specifically developed for fast and easy isolation of highly purified cells that are ready for downstream applications. It marks the culmination of many years of work, which included examining more than 230 bone marrow aspirates from multiple myeloma patients, precision studies of inter- and intra-laboratory reproducibility, and limit of detection and interference studies. The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.
1Padala et al. 2021 Med Sci (Basel)
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326396951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 15:00:00 CET | Press release
Agreement to deliver Sila’s Titan Silicon® Si/C anode to Panasonic’s U.S. manufacturing sites, fortifying domestic battery supply chain resilience and advanced technology capabilities. Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release fe
Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization18.11.2026 15:00:00 CET | Press release
Rimini Cloud™ for SAP offers a smart path to modern cloud infrastructure without the risk of ERP reimplementation, forced subscription conversion or disruption to existing SAP investments Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced an expanded strategic partnership with American Digital Corporation to give SAP licensees a lower-risk, more flexible path to cloud modernization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118330258/en/ Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization Through the expanded relationship, American Digital will serve as a solution partner for Rimini Cloud™ for SAP, helping SAP ECC and S/4HANA licensees move their existing SAP systems to modern cloud infrastructure without requiring ERP reim
Two Cessna SkyCourier Aircraft Enter Aero-Medical Service With Delivery to Tassili Travail Aérien18.11.2026 15:00:00 CET | Press release
First SkyCouriers flying in Africa will support medical evacuation missions in Algeria’s energy sector Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced it has delivered two Cessna SkyCourier aircraft equipped for aero-medical missions to Tassili Travail Aérien (TTA) of Algeria. The aircraft are the first aero-medical SkyCouriers in Africa and the first customer SkyCouriers to enter service on the continent, expanding the aircraft’s global presence and demonstrating its versatility for critical special missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015092210/en/ Textron Aviation completes delivery of Africa’s first two aero-medical equipped Cessna SkyCourier aircraft to Tassili Travail Aérien, also marking the first SkyCourier deliveries in Africa, expanding the aircraft’s special-mission capabilities. The two aircraft will support TTA’s passenger transportation and aero-medical evacuati
KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 14:28:00 CET | Press release
The Canadian hospitality brand expands its collection across more than 33 countries and more than 500 cities, introducing exclusive member privileges through KŌZĒ Privé. KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, kn
Blue Yonder Announces New Leadership18.11.2026 14:03:00 CET | Press release
CTO Salil Joshi Named Interim CEO to Lead Next Phase of Growth with Accelerated Innovation and Expanded Use of Company’s Technology Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
